FIH XON7 in Advanced/Metastatic Solid Tumors

This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid tumor types and to further evaluate safety and tolerability of XON7 at RP2D.

Inclusion Criteria: 1. Provide signed, written informed consent. 2. Male and female participant, age ≥ 18 years old (at the time consent is obtained) 3. Solid tumors indications: * Participant in phase I, must have a histologically or cytologically confirmed advanced or metastatic solid tumors for which no effective standard therapy is available. All tumor types except glioblastoma, could be included. * Participant in phase II, must have histologically or cytologically confirmed advanced or metastatic solid tumors of the following: NSCLC, gastro-esophageal adenocarcinoma, CRC, pancreatic cancer, Sarcoma, TNBC, or ovarian cancer. 4. Line of treatment: Participant must have solid tumors progressing after ≤ 4 lines of standard appropriate anticancer therapies for the specific tumor type, or for which the patient is ineligible. Participants whose cancers harbor molecular alterations for which targeted therapy is standard of care should have received health authority-approved appropriate targeted therapy for their tumor types before enrollment. 5. Measurable disease per RECIST version 1.1 - v5 6. (ECOG) performance status (PS) 0-1 7. Life expectancy of at least 12 weeks. 8. Adequate organ function 9. QT duration corrected for heart rate by Fridericia's formula (QTcF) \